hCCN4

Nomenclature

C57BL/6JSmo-Ccn4tm(hCCN4)Smoc

Cat. NO.

NM-HU-220519

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Ccn4

Model Description

The endogenous mouse Ccn4 gene was replaced by human CCN4 gene.

Validation Data

image.png

Fig.1 Detection of CCN4 expression in ovary by RT-PCR. Ovary RNA was extracted from 6-week-old female wild-type C57BL/6 (WT)(n=2) and homozygous hCCN4 knockin mice (HO) (n=2), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers. Mouse Ccn4 mRNA (262 bp) was detectable only in wild-type C57BL/6 mice. Human CCN4 mRNA (265 bp) was detectable only in homozygous hCCN4 knockin mice but not in wild-type mice. Mouse Ccn4 mRNA (262 bp) was detectable only in wild-type C57BL/6 mice. Human CCN4 mRNA (265 bp) was detectable only in homozygous hCCN4 knockin mice but not in wild-type mice. 

image.png

Fig.2 Detection of CCN4 expression in hCCN4 mice by WB. Lysates of heart, liver, spleen, lung and kidney tissues were collected from 6-week-old female wild-type C57BL/6 mice and 6-week-old female homozygous hCCN4 knockin mice, and then analyzed by western blot with anti-CCN4 antibody. CCN4 was detectable in heart, liver, spleen, lung and kidney from both WT C57BL/6 and HO hCCN4 knockin mice, as the antibody was cross-reactived between human and mouse CCN4. 

Abbr. HO, homozygous; WT, wild type; PC, positive control, Caco2 cells.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more